PR Newswire
PALO ALTO, Calif., Nov. 29, 2016
PALO ALTO, Calif., Nov. 29, 2016/PRNewswire/ - AirXpanders, Inc., (ASX: AXP) (AirXpanders or Company), a medicinal gadget organization concentrated on the plan, fabricate, deal and circulation of the AeroForm Tissue Expander System, declared that essential trial information from its XPAND examine on AeroForm was distributed in the December issue of Plastic and Reconstructive Surgery, the official diary of the American Society of Plastic Surgeons. AeroForm is presently accessible in Australia and under survey with the U.S. Sustenance and Drug Administration.
AeroForm is intended to offer ladies who pick reconstructive surgery taking after a mastectomy a without needle elective for tissue extension. AeroForm is enacted by a handheld remote controller that manages little measures of carbon dioxide (CO2) up to three times each day, to steadily extend the tissue to plan for reproduction. With the push of a catch from a remote controller, the modified measure of CO2 is conveyed in seconds, permitting the patient to proceed with her day by day exercises while get ready for recreation.
The XPAND concentrate on assessed AirXpanders' AeroForm Tissue Expander System contrasted with customary saline expanders in a randomized, controlled trial that included 150 patients crosswise over 17 destinations in the U.S. Concentrate on information showed that with AeroForm, patients could finish tissue extension in a normal of 21 days, contrasted with a normal of 46 days for the saline gathering. The concentrate additionally showed that both study bunches accomplished effective trade to an embed with comparable wellbeing profiles. AirXpanders presented the aftereffects of the XPAND study to the U.S. Nourishment and Drug Administration (FDA) as a component of the Company's all over again dossier, submitted before the end of last year.
"Dread of a tedious and conceivably uncomfortable therapeutic process can stop ladies who have experienced mastectomy from having recreation," said Jeffrey Ascherman, M.D., site head of the Division of Plastic Surgery NewYork-Presbyterian/Columbia University Medical Center and important specialist for AirXpanders' U.S. XPAND ponder. "This study is additional proof that AeroForm could enhance the standard of look after remaking, empowering ladies to finish reproduction quicker and with more prominent control over the procedure."
"Distribution of the XPAND information approves AeroForm and its capability to give plastic specialists and patients with what we accept is one of the primary real headways in two-organize bosom recreation in over 40 years," said Scott Dodson, president and CEO, AirXpanders. "We anticipate working with FDA to convey this progressive innovation to specialists and ladies in the U.S. furthermore, proceeding with our endeavors to grow access to AeroForm all inclusive."
A conceptual of the XPAND information distributed in the diary is accessible here.
Organization
Media
Scott Dodson
President and CEO
Tel: +1 (650)- 390-9008
Email: sdodson@airxpanders.com
Michelle Thaler/Wendy Ryan
MSLGROUP
(781) 684-0770
AirXpanders@mslgroup.com
About AirXpanders:
Established in 2005, AirXpanders, Inc. (www.airxpanders.com) plans, produces and markets imaginative restorative gadgets to enhance bosom recreation. The organization's leader item, the AeroForm Tissue Expander System, is utilized as a part of patients experiencing two-arrange bosom remaking taking after mastectomy. Headquartered in Palo Alto, California, AirXpanders is focused on furnishing patients and specialists with best-in-class items that are made under strict outline and quality gauges. AirXpanders' vision is to be the worldwide pioneer in reconstructive surgery items and to end up distinctly the standard of care in two-organize bosom reproduction. AirXpanders is a publically recorded organization on the Australian Stock Exchange under the image AXP. The AeroForm Tissue Expander System is not cleared or endorsed for use in the United States and is for investigational utilize as it were. AeroForm is cleared for commercialization in Europe and Australia
Forward-Looking Statements
This declaration contains or may contain forward-looking explanations that depend on administration's convictions, suspicions and desires and on data as of now accessible to administration. All announcements that address working execution, occasions or improvements that we expect or foresee will happen later on are forward-looking articulations, including without restriction our desires concerning our capacity to get FDA endorsement for our item; to popularize our item; our capacity to acquire repayment for our item; remedial points of interest of our item, and market open door for our item. Administration trusts that these forward-looking articulations are sensible as and when made. You ought not put undue dependence on forward-looking articulations since they talk just as of the date when made. AirXpanders does not accept any commitment to openly overhaul or reconsider any forward-looking articulations, whether as an aftereffect of new data, future occasions or something else. AirXpanders may not really accomplish the arrangements, projections or desires uncovered in forward-looking explanations, and real outcomes, improvements or occasions could contrast substantially from those unveiled in the forward-looking articulations.
More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=193812#.WD6ri9J96M8#ixzz4RUH8J5PV
PALO ALTO, Calif., Nov. 29, 2016
PALO ALTO, Calif., Nov. 29, 2016/PRNewswire/ - AirXpanders, Inc., (ASX: AXP) (AirXpanders or Company), a medicinal gadget organization concentrated on the plan, fabricate, deal and circulation of the AeroForm Tissue Expander System, declared that essential trial information from its XPAND examine on AeroForm was distributed in the December issue of Plastic and Reconstructive Surgery, the official diary of the American Society of Plastic Surgeons. AeroForm is presently accessible in Australia and under survey with the U.S. Sustenance and Drug Administration.
AeroForm is intended to offer ladies who pick reconstructive surgery taking after a mastectomy a without needle elective for tissue extension. AeroForm is enacted by a handheld remote controller that manages little measures of carbon dioxide (CO2) up to three times each day, to steadily extend the tissue to plan for reproduction. With the push of a catch from a remote controller, the modified measure of CO2 is conveyed in seconds, permitting the patient to proceed with her day by day exercises while get ready for recreation.
The XPAND concentrate on assessed AirXpanders' AeroForm Tissue Expander System contrasted with customary saline expanders in a randomized, controlled trial that included 150 patients crosswise over 17 destinations in the U.S. Concentrate on information showed that with AeroForm, patients could finish tissue extension in a normal of 21 days, contrasted with a normal of 46 days for the saline gathering. The concentrate additionally showed that both study bunches accomplished effective trade to an embed with comparable wellbeing profiles. AirXpanders presented the aftereffects of the XPAND study to the U.S. Nourishment and Drug Administration (FDA) as a component of the Company's all over again dossier, submitted before the end of last year.
"Dread of a tedious and conceivably uncomfortable therapeutic process can stop ladies who have experienced mastectomy from having recreation," said Jeffrey Ascherman, M.D., site head of the Division of Plastic Surgery NewYork-Presbyterian/Columbia University Medical Center and important specialist for AirXpanders' U.S. XPAND ponder. "This study is additional proof that AeroForm could enhance the standard of look after remaking, empowering ladies to finish reproduction quicker and with more prominent control over the procedure."
"Distribution of the XPAND information approves AeroForm and its capability to give plastic specialists and patients with what we accept is one of the primary real headways in two-organize bosom recreation in over 40 years," said Scott Dodson, president and CEO, AirXpanders. "We anticipate working with FDA to convey this progressive innovation to specialists and ladies in the U.S. furthermore, proceeding with our endeavors to grow access to AeroForm all inclusive."
A conceptual of the XPAND information distributed in the diary is accessible here.
Organization
Media
Scott Dodson
President and CEO
Tel: +1 (650)- 390-9008
Email: sdodson@airxpanders.com
Michelle Thaler/Wendy Ryan
MSLGROUP
(781) 684-0770
AirXpanders@mslgroup.com
About AirXpanders:
Established in 2005, AirXpanders, Inc. (www.airxpanders.com) plans, produces and markets imaginative restorative gadgets to enhance bosom recreation. The organization's leader item, the AeroForm Tissue Expander System, is utilized as a part of patients experiencing two-arrange bosom remaking taking after mastectomy. Headquartered in Palo Alto, California, AirXpanders is focused on furnishing patients and specialists with best-in-class items that are made under strict outline and quality gauges. AirXpanders' vision is to be the worldwide pioneer in reconstructive surgery items and to end up distinctly the standard of care in two-organize bosom reproduction. AirXpanders is a publically recorded organization on the Australian Stock Exchange under the image AXP. The AeroForm Tissue Expander System is not cleared or endorsed for use in the United States and is for investigational utilize as it were. AeroForm is cleared for commercialization in Europe and Australia
Forward-Looking Statements
This declaration contains or may contain forward-looking explanations that depend on administration's convictions, suspicions and desires and on data as of now accessible to administration. All announcements that address working execution, occasions or improvements that we expect or foresee will happen later on are forward-looking articulations, including without restriction our desires concerning our capacity to get FDA endorsement for our item; to popularize our item; our capacity to acquire repayment for our item; remedial points of interest of our item, and market open door for our item. Administration trusts that these forward-looking articulations are sensible as and when made. You ought not put undue dependence on forward-looking articulations since they talk just as of the date when made. AirXpanders does not accept any commitment to openly overhaul or reconsider any forward-looking articulations, whether as an aftereffect of new data, future occasions or something else. AirXpanders may not really accomplish the arrangements, projections or desires uncovered in forward-looking explanations, and real outcomes, improvements or occasions could contrast substantially from those unveiled in the forward-looking articulations.
More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=193812#.WD6ri9J96M8#ixzz4RUH8J5PV
No comments:
Post a Comment
Note: only a member of this blog may post a comment.